Her-2/neutrastuzumablapatinibtruncated Her-2PTENp27(kip)topoisomerase II alpharesistanceHer-2/neu-positive tumors account for approximately 20% of all breast cancer and these tumors carry poor prognosis. Trastuzumab and lapatinib are 2 agents that have gained FDA approval for treating Her-2/...
Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK: Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85-95, 1993 Google Scholar Lewis GD, Figari I, Fendly B, Wong WL,...
p66ShcIsoform Down-Regulated and Not Required for HER-2/neu Signaling Pathway in Human Breast Cancer Cell Lines withHER-2/neuOverexpression TheHER2/neuprotooncogene encodes a transmembrane receptor tyrosine kinase ofMr185 kDa (called p185) which is structurally and functionally homologous to th......
1.Tandon A, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-8. 2.Mitri Z, et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Ad...
Seediscussions,stats,andauthorprofilesforthispublicationat:https://.researchgate.net/publication/15093941 Her-2/neuExpressioninNode-negativeBreast Cancer:DirectTissueQuantitationby ComputerizedImageAnalysisandAssociationof OverexpressionwithIncreasedRiskofRecurrent Di... ARTICLEinCANCERRESEARCH·NOVEMBER1993 ImpactFactor...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
Human epidermal growth factor receptor 2 (HER2-neu) is an important prognostic factor associated with worsened disease-free survival and overall survival in breast cancer patients; however, the prognosis of T1a,b,N0,M0 HER2-neu positive breast cancer has not been clearly determined. Trastuzumab has...
Prognostic and predictive value of HER2/neu oncogene in breast cancer Assessment of HER2/neu oncogene has been used as both a prognostic and predictive marker for breast cancer. However, the choice of the best method to asses... S Masood,MM Bui - 《Microsc Res Tech》 被引量: 243发表: 20...
Breast cancer (BRCA) has a high incidence and mortality rate among women. Different molecular subtypes of breast cancer have different prognoses and require personalized therapies. It is imperative to find novel therapeutic targets for different molecula
M. Elizabeth H. Hammond MD Corresponding author Correspondence toJeffrey Prichard DO. Prichard, J., Hicks, D.G., Hammond, M.E.H. (2015). Predictive Biomarkers in Breast Cancer: ER, PR and Her-2/neu. In: Lin, F., Prichard, J. (eds) Handbook of Practical Immunohistochemistry. Springer...